464
Participants
Start Date
May 23, 2019
Primary Completion Date
October 1, 2024
Study Completion Date
September 30, 2028
Targeted Lung Denervation (TLD)
Targeted Lung Denervation (TLD) Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.
Optimal Medical Care
Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
University of Pittsburgh Medical Center (UPMC), Pittsburgh
Temple Lung Center, Philadelphia
Duke University, Durham
First Health of the Carolinas, Pinehurst
Medical University of South Carolina (MUSC), Charleston
Hopital Larrey, Toulouse
Ascension St. Vincent's, Jacksonville
University of Alabama at Birmingham (UAB) Lung Health Center, Birmingham
CHU de Grenoble, Grenoble
University of Louisville, Louisville
Ohio State University Wexner Medical Center, Columbus
University of Michigan, Ann Arbor
Spectrum Health Medical Group, Grand Rapids
Suburban Lung Associates, Elk Grove Village
University of Chicago, Chicago
Washington University, St Louis
Houston Methodist Hospital, Houston
St. Davids HealthCare, Georgetown
HonorHealth, Phoenix
Harbor UCLA, Torrance
UC Davis, Sacramento
Lahey Hospital & Medical Center, Burlington
Krankenhaus Nord - Klinik Floridsdorf, Vienna
Hopital de la Cavale Blanche, Brest
Arnaud de Villeneuve Hospital, Montpellier
Hopital Pasteur, Nice
Bichat-Claude Bernard Hospital, Paris
CHU de Reims, Reims
CHU de Strasbourg, Strasbourg
Thorax Klinik Heidelberg, Heidelberg
UMC, Amsterdam
University Medical Center Groningen (UMCG), Groningen
Royal Brompton Harefield Trust, London
Lead Sponsor
Nuvaira, Inc.
INDUSTRY